Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer

Objectives To investigate the recent real‐world use of first‐generation antiandrogens (FGAs) in metastatic castration‐resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients and Methods The electronic CRPC Australian Database (ePAD) was interrogated to identify pat...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2021-10, Vol.128 (S1), p.18-26
Main Authors: Kelly, Richard, Anton, Angelyn, Wong, Shirley, Shapiro, Julia, Weickhardt, Andrew, Azad, Arun, Kwan, Edmond Michael, Spain, Lavinia, Muthusamy, Arun, Torres, Javier, Parente, Phillip, Parnis, Francis, Goh, Jeffrey, Joshua, Anthony, Pook, David, Baenziger, Olivia, Gibbs, Peter, Tran, Ben
Format: Article
Language:English
Subjects:
Aged
Androgen Antagonists - therapeutic use
Antiandrogens
Castration
Cohort Studies
first‐generation antiandrogen
Humans
Male
Metastases
Metastasis
Middle Aged
Neoplasm Metastasis
Patients
PCSM
Prostate cancer
ProstateCancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Prostatic Neoplasms, Castration-Resistant - therapy
real‐world data
Retrospective Studies
Survival
Treatment Outcome
uroonc
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To investigate the recent real‐world use of first‐generation antiandrogens (FGAs) in metastatic castration‐resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients and Methods The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan–Meier method and groups compared using log‐rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model. Results We identified 634 patients with mCRPC, enrolled in ePAD between January 2016 and March 2019, including 322 (51%) who received FGAs. The median follow‐up was 21.9 months. Patients treated with FGAs were more likely to have lower International Society of Urological Pathologists (ISUP) grade group (P = 0.04), longer median time to CRPC (25.6 vs 16.0 months, P 
ISSN:1464-4096
1464-410X
DOI:10.1111/bju.15364